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ABSTRACT
Introduction: Point-of-care in vitro diagnostics
(POC-IVD) are increasingly becoming widespread as an
acceptable means of providing rapid diagnostic results
to facilitate decision-making in many clinical pathways.
Evidence in utility, usability and cost-effectiveness is
currently provided in a fragmented and detached
manner that is fraught with methodological challenges
given the disruptive nature these tests have on the
clinical pathway. The Point-of-care Key Evidence Tool
(POCKET) checklist aims to provide an integrated
evidence-based framework that incorporates all
required evidence to guide the evaluation of POC-IVD
to meet the needs of policy and decisionmakers in the
National Health Service (NHS).
Methods and analysis: A multimethod approach will
be applied in order to develop the POCKET. A thorough
literature review has formed the basis of a robust Delphi
process and validation study. Semistructured interviews
are being undertaken with POC-IVD stakeholders,
including industry, regulators, commissioners,
clinicians and patients to understand what evidence is
required to facilitate decision-making. Emergent themes
will be translated into a series of statements to form a
survey questionnaire that aims to reach a consensus in
each stakeholder group to what needs to be included in
the tool. Results will be presented to a workshop to
discuss the statements brought forward and the optimal
format for the tool. Once assembled, the tool will be
field-tested through case studies to ensure validity and
usability and inform refinement, if required. The final
version will be published online with a call for
comments. Limitations include unpredictable sample
representation, development of compromise position
rather than consensus, and absence of blinding in
validation exercise.
Ethics and dissemination: The Imperial College
Joint Research Compliance Office and the Imperial
College Hospitals NHS Trust R&D department have
approved the protocol. The checklist tool will be
disseminated through a PhD thesis, a website, peer-
reviewed publication, academic conferences and formal
presentations.
INTRODUCTION
Point-of-care in vitro diagnostics (POC-IVD)
provide rapid results near patient or at the
bedside to facilitate real-time clinical
decision-making. POC-IVD devices are well
established in medical, industrial and military
environments. Clinical examples include
blood glucose, anticoagulation and preg-
nancy testing. These offer potential advan-
tages such as decreasing the time to deﬁnitive
treatment, improved cost-effectiveness,1 2
better patient adherence with treatment and
increased patient satisfaction.3 However, bar-
riers to the implementation of POC-IVD tech-
nology exist, including the increased cost on
a test-by-test basis, reduced accuracy, unclear
clinical pathway beneﬁts and associated main-
tenance and governance responsibilities.4
Many of these barriers may be overcome if
better evidence was available. With a
POC-IVD diagnostic industry that is expand-
ing rapidly, with an estimated 29% share of
the in vitro diagnostic market5 and predicted
to be worth US$24 billion by 2018,6 it is
important that we have the methodology to
evaluate these devices in a valid, efﬁcient and
timely manner.
Strengths and limitations of this study
▪ Multimethod approach incorporating all stakeholders.
▪ Agreement of independent National Institute of
Health Research Diagnostic Evidence Co-operatives
to prospectively field-test and provide feedback on
the developed tool.
▪ Collaborative approach of academia and industry.
▪ Delphi methodology may lead to a compromise
position rather than true consensus.
▪ Small sample size with unpredictable
representation.
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Point-of-care tests are a disruptive innovation that is
used by both healthcare professionals and patients at
clinical facilities or at home to prompt an immediate
clinical decision. Evidence generation on such technol-
ogy should include not only the assessment of the
device itself, but also the test processes (sample collec-
tion, test procedure and result output) and system
dynamics (training, data transfer, patient safety and
intervention). Clinical pathway examination is funda-
mental to incorporate healthcare beneﬁts, consequences
of misdiagnosis and the impact on alternative diagnostic
workforce. Accumulating appropriate evidence results in
a long lead-time from innovation to clinical adoption,
with some technologies never making the transition to
the bedside.
Quality evidence on POC-IVD is required for regula-
tion, policy making and implementation. Currently, the
pathway for evidence generation in diagnostics is frag-
mented and does not follow the linear sequence of eva-
luations that has become mainstream for drug
evaluation.7 Diagnostic accuracy is often established with
poor methodological quality8 and alone rarely provides
sufﬁcient justiﬁcation for device adoption. Evidence is
required to demonstrate the behaviour changes induced
by the test result and the consequences to patient
outcome. Usability testing and economic analysis are
commonly performed in isolation. This multifaceted
approach is time consuming, expensive and stands as a
barrier to devices translating from industry to the health-
care environment. Given the considerable overlap in
these methodology work streams, a multidimensional
concurrent approach to evidence generation would be
able to add signiﬁcant efﬁciencies to the evidence gen-
eration pathway.
There are several reports in the medical literature to
improve the quality of evidence in diagnostic devices.
Examples include the standards for reporting of diag-
nostic accuracy studies (STARD)9 initiative to improve
accuracy and completeness in diagnostic accuracy
studies; a quality assessment tool for diagnostic accuracy
studies (QUADAS-2)10 to evaluate the risk of bias in
primary diagnostic accuracy studies; and the consoli-
dated health economic evaluation reporting standards
statement (CHEERS)11 for reporting health economic
evaluations. This is paralleled in the design literature by
standards published by the International Organisation
for Standardisation (ISO) and British Standards (BS),
including BS EN 62366,12 that relates to usability engin-
eering in medical devices. The National Institute for
Health and Clinical Excellence (NICE) has published a
Diagnostics Assessment Programme Manual13 outlining
what evidence is required for their appraisal process and
how this should be synthesised. However, all these stan-
dards and guidelines were speciﬁc to a particular focus
and there is an absence of an integrated framework to
present the multidimensional evidence ‘package’ that is
required by decisionmakers when evaluating new
medical technologies.
The aim of this study is to develop a Point-Of-Care Key
Evidence Tool (POCKET); as a ‘one-stop’ multidimen-
sional evaluation checklist and reporting standard
incorporating validity, utility usability, cost-effectiveness
and patient experience in POC-IVD at a device, process
and system level. The motivation for POCKET is to aid
industry and academic researchers when undergoing
the development and evaluation of POC-IVD to ensure
the combined evidence requirements of users and
policy decisionmakers are met efﬁciently, reducing the
lead time for the adoption of new technologies and
allowing demonstrable beneﬁts to patients and the
National Health Service to be effectively realised.
METHODS
The POCKET checklist will be developed and reﬁned by
a multimethod approach utilising stakeholders in the
POC-IVD ﬁeld and experts in methodology. The study
design is outlined in ﬁgure 1. A semistructured interview
study will identify emergent themes to guide a Delphi
study that will generate an expert consensus on tool
inclusion. This will be presented at a workshop to
develop the initial draft tool that will be reﬁned and vali-
dated by a series of case studies to ﬁeld-test the tool.
Study status
Recruitment and semistructured interviews (stage 1)
started in August 2014. The questionnaire round of the
Delphi survey will be sent out in August 2015 and the
expert workshop is planned for the ﬁnal quarter of
2015.
A comprehensive literature review preceded the inter-
view protocol development to identify the potential evi-
dence requirements for tool inclusion and at what stage
of the device development pathway these reports can be
generated. Electronic searches of medical and design
databases were searched using a search strategy consist-
ing of keywords and MeSH headings designed to iden-
tify articles related to POC-IVD.
Stage 1: Delphi process
Delphi round 1: Semistructured interviews
A semistructured interview study is being undertaken
with stakeholders relating to POC-IVD in order to
collect primary data. Five stakeholder groups are being
invited: patients and patient group representatives, clini-
cians, industry, regulators and commissioners. A
minimum of eight participants from each group will be
interviewed as a pragmatic sample size, given time and
resources. However, the ﬁnal number of participants will
be guided by the interview results, as more interviews
will be carried out until no new themes emerge. The
majority of participants will be from the UK, but where
relevant experience or expertise exists abroad such parti-
cipants will be included in the study. Every effort will be
made to recruit a representative and diverse sample
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across each participant group. Inclusion criteria and
method of recruitment will vary by stakeholder group:
▸ Patients are recruited from the public through the
patient information forum, patient associations and
diagnostic research public engagement events. They
will have experience of home POC-IVD use for the
monitoring of chronic disease. They will not be dir-
ectly recruited from the NHS. Patient records will not
be accessed for recruitment.
▸ Industry representatives include personnel currently
employed by a point-of-care industry and are
recruited by an invitation included in their trade asso-
ciation BIVDA (British In Vitro Diagnostics
Association) newsletter.
▸ Clinicians are recruited directly by electronic mail
based on expertise in point-of-care diagnostics as
demonstrated by academic output or their role on
point-of-care committees.
▸ Commissioners include current members of clinical
commissioning groups in northwest London and are
recruited directly by electronic mail following an
introduction from the Department of Primary Care
and Public Health at Imperial College.
▸ Regulators will include current members of the NICE
Diagnostic Advisory Committee and the Medicines
and Healthcare Products Regulatory Agency
(MHRA), and are recruited through their partner-
ships with the Diagnostic Evidence Co-operative.
Exclusion criteria include those unable to give informed
consent to participate in the study, inability to understand
and communicate in English, and members of the public
from vulnerable groups (those under 18, prisoners, those
in dependent relationships, the mentally ill).
The interview structure has been designed by a clin-
ician ( JRH) in conjunction with an expert in qualitative
research (SM) to permit the collection of quantitative
and qualitative data while allowing for ﬂexibility and ori-
ginal suggestions. The interviews aim to understand the
role different stakeholders have and the evidence that is
required at each step in the adoption pathway of
POC-IVD. This pathway includes device design, evalu-
ation and implementation. Interviews are tailored to the
role and level of experience of the interviewee, with sig-
niﬁcant tailoring required for interviews with patients.
This ensures the interviews remain relevant to the differ-
ent stakeholders. In the situation that the interviewee
has a role in more than one stakeholder group, the
interview focuses on their primary interest with subse-
quent roles recorded for analysis.
The interview questions were piloted to ﬁne-tune
the protocol prior to the study interviews. Interviews
will be carried out face-to-face by one interviewer
( JRH), with telephone or ‘Skype’ interviews reserved
for when this is not feasible. Interviews will last for
approximately 30–40 min, be digitally recorded and
then transcribed verbatim for analysis. The main
researcher and an additional team member with
expertise in qualitative research will coanalyse the data
independently in order to minimise bias. Initially,
interview data will be coded based on the predeter-
mined interview themes; it is expected that additional
themes will emerge and be coded during the interview
analyses. If required, participants will be contacted to
clarify interpretation of data. Data will be analysed
with NVivo V.10.1.1 software (QSR International,
Melbourne, Victoria, Australia).
Delphi round 2: Delphi questionnaire summarising opinions
and reaching consensus
Round 2 will allow experts to respond to questions that
aim to reach a consensus on the required evaluation
process for point-of-care diagnostic tests and add to the
evidence base for the development of the POCKET
checklist for multidimensional evidence generation.
All emergent themes relating to evidence require-
ments from the interview study will be translated into a
series of statements and the survey questionnaire will be
sent to an expert panel comprised of those interviewed
in round 1 (with the exception of patients) as well as
experts in research methodology identiﬁed by academic
output. The Delphi study cohort will include a
minimum of eight participants from each stakeholder
group. As for round 1, this is a pragmatic sample size
given the time and resources available for the study. The
questionnaire statements will be responded to on a ﬁve-
point Likert scale (1 (strongly disagree) to 5 (strongly
agree)) in respect to checklist inclusion. Responders will
also be able to add free text comments with each state-
ment if needed to justify responses or suggest items that
should be added and have been dismissed. The survey
will be administered online using Qualtrics software
(Qualtrics Labs Inc, Provo, UT) with personalised invita-
tions sent out by electronic mail. Reminders will be sent
at 4 and 6 weeks after initial contact for non-responders.
Survey responses will be entered into SPSS and descrip-
tive analyses carried out (frequencies, median scores,
range of scores).
Figure 1 Study outline.
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Delphi round 3: Reaching consensus
The survey will be repeated following feedback to the
experts on the collated responses from the previous
round. Any new items suggested in free text responses to
round 2 will be added at this stage. This method will allow
participants to reconsider their responses in light of the
group results and they will be encouraged to justify their
responses when there is a signiﬁcant degree of divergence.
This process will be repeated until consensus is reached.
The aim of the POCKET tool is to meet the evidence
requirements of all stakeholders. Therefore, stakeholder
groups will be analysed individually and any statement
deemed necessary by at least one group will be included in
the tool. Consensus will be set at ≥80% across items that
receive ≥4 (agree or strongly agree). Cronbach’s α will be
used to assess reliability. Previous studies14–16 have set a
Cronbach’s α of ≥0.8 as representative of an acceptable
measure of internal reliability and this, therefore, will be
the priori deﬁnition of consensus for this study.
Stage 2: Expert workshop
Development of POCKET
A 2-day consensus workshop will be arranged for invited
experts from researchers, editors, methodologists, indus-
try and professional organisations. The workshop will
follow the approach taken by Bossuyt et al in the devel-
opment of the STARD guidelines.8 The workshop will
start with a presentation of the results from the Delphi
questionnaire followed by a mixture of small group ses-
sions and plenary sessions. These sessions will aim to
evaluate and justify the list of statements brought
forward from the Delphi survey, and discuss the optimal
format and phrasing of the checklist tool. Small multista-
keholder groups will focus on a group of related state-
ments with their outputs discussed at plenary sessions.
A ﬁrst draft of the POCKET checklist will be assembled
by the end of day 1.
Validation of POCKET
The draft of the POCKET checklist will be discussed on
the second day of the workshop and additional changes
made. The checklist will be ﬁeld-tested through a series
of case studies of POC-IVD devices to ensure consistency,
validity and usability. POC-IVD devices that have had
demonstrable market success or failure in respect to
clinical adoption will be identiﬁed through industry and
expert feedback obtained during the Delphi process.
Small groups will be provided with published research
articles, conference abstracts and input from industry
relating to devices and asked to retrospectively assess
their adherence to the POCKET checklist. The groups
will be not be informed to market results; however, it is
possible that through their own experience they will
already have an insight into the level of success many
devices have had.
The output data from the groups will be analysed and
a comparative evaluation undertaken to determine if
devices that met the checklist requirements performed
better in the IVD market and had successful implemen-
tation into the NHS. This exercise will inform further
amendments to the tool if required. The ﬁnal POCKET
checklist will be published on the NIHR Diagnostic
Evidence Co-operative London website with a call for
comments. Following dissemination of the POCKET
checklist users, including the NIHR Diagnostic Evidence
Co-operatives in Leeds, Newcastle and Oxford, will be
asked to provide feedback and further validation will be
undertaken by real-world use of the tool in prospective
POC device evaluations.
Ethical concerns and dissemination
Participation in this study is voluntary. During the
recruitment phase, all potential participants will be pro-
vided with a detailed information sheet in order to allow
them to make an informed decision regarding their par-
ticipation. The right of the participant to refuse to par-
ticipate or withdraw at any time without giving reasons
will be respected. Initially, informed consent was
obtained for the interview study in isolation and these
participants will require a further consent process for
inclusion in subsequent Delphi rounds. However, an
amendment was approved on 27 October 2014 requiring
consent for the interview study and Delphi process
together. No ﬁnancial or other remuneration will be dir-
ectly offered to participants. However, in some circum-
stances an honorarium will be offered to the practice of
participants to compensate for their missed clinical
time. This was agreed following advice from the
Imperial College School of Primary Care. The protocol
has been approved by the Joint Research Compliance
Ofﬁce Imperial College, London, and the Imperial
College Hospitals NHS Trust R&D department (ICREC
References 14IC2186, 14SM2190). The checklist tool will
be disseminated through a PhD thesis ( JRH), the
NIHR-DEC website, peer-reviewed publications, aca-
demic conferences and formal presentations to industry,
policymakers and practitioners.
LIMITATIONS
This study design has several limitations. Many of these
are common to qualitative research techniques and par-
ticularly, the Delphi process. The Delphi process may
lead to a compromise position rather than a true con-
sensus. The sample size of at least eight participants in
each stakeholder group is small and the extent to which
included participants will be representative is unknown.
The recruitment protocol aims to recruit a broad selec-
tion of participants but the authors acknowledge that a
degree of convenience sampling may be required. This
could only be overcome by a random sampling approach
that would not be feasible in the present study. The val-
idation exercise that will be undertaken as part of the
workshop is not blinded; therefore, the previous experi-
ences of participants in respect to a particular technol-
ogy may introduce a bias. A period of reﬁnement has
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been included at the end of the study so that any evi-
dence requirements not identiﬁed during the study can
be added if required.
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